Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. <\/p>\n
Kyle Grillot | Bloomberg | Getty Images<\/p>\n
Johnson & Johnson<\/a> said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an interim analysis.<\/p>\n The drug, JNJ-5939, was being tested in patients with atopic dermatitis, or eczema, a skin condition that causes inflammation, redness and intense itching.<\/p>\n The drug was well-tolerated but did not meet the “high-bar” efficacy required to advance development, the company said.<\/p>\n Johnson & Johnson said it remains committed to developing treatments for atopic dermatitis, a chronic condition that affects more than 100 million people worldwide.<\/p>\n The company is developing other experimental treatments for atopic dermatitis, including bispecific antibodies NM26, PX128 and PX130, as well as an oral STAT6 inhibitor, KP\u2011723.<\/p>\n Eczema has multiple approved treatments, such as Sanofi<\/a> and Regeneron’s<\/a> Dupixent, AbbVie’s<\/a> Rinvoq, Pfizer’s<\/a> Cibinqo, Eli Lilly’s<\/a> Ebglyss, as well as some generic drugs such as cetirizine.<\/p>\n","protected":false},"excerpt":{"rendered":"Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…\n","protected":false},"author":3,"featured_media":473027,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[6798,9165,81,37520,210,1141,9166,1142,1876,15008,69142,69144,67,132,68],"class_list":{"0":"post-473026","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-abbvie-inc","9":"tag-biotech-and-pharmaceuticals","10":"tag-business-news","11":"tag-eli-lilly-and-co","12":"tag-health","13":"tag-health-care","14":"tag-health-care-industry","15":"tag-healthcare","16":"tag-johnson-johnson","17":"tag-pfizer-inc","18":"tag-regeneron-pharmaceuticals-inc","19":"tag-sanofi-sa","20":"tag-united-states","21":"tag-unitedstates","22":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115786489901234953","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/473026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=473026"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/473026\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/473027"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=473026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=473026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=473026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}